Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,387 matching trials from the live ClinicalTrials.gov search.
Filters: Tucson, Arizona Clear all
Terminated Not applicable Interventional

Early Coronary Angiography Versus Delayed Coronary Angiography

NCT02387398
View directory record Official record
Conditions
Out-of-Hospital Cardiac Arrest, Hypothermia, Cardiac Arrest
Interventions
Early Angiography
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Tucson, Arizona • Portland, Maine • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

NCT00033293
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
Other · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 8 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 22, 2026, 2:24 PM EDT
Active, not recruiting No phase listed Observational

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

NCT04091984
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Prospera
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation

NCT01004055
View directory record Official record
Conditions
Wound Healing, Wound Infection
Interventions
Procellera™ Antimicrobial Wound Dressing, ACTICOAT™ Antimicrobial Barrier Dressing, Mepilex® Ag Silver Foam Dressing
Device · Drug
Lead sponsor
Vomaris Innovations
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Oro Valley, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 29, 2009 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

NCT01369355
View directory record Official record
Conditions
Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
Interventions
Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
77
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00002969
View directory record Official record
Conditions
Lung Cancer
Interventions
paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 22, 2026, 2:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

NCT03811002
View directory record Official record
Conditions
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
532
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

NCT00483977
View directory record Official record
Conditions
Osteoarthritis
Interventions
Oxycodone, Placebo, PF-000592379
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
21
States / cities
Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2011 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

NCT00056407
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years · Male only
Enrollment
8,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
297
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 4 Interventional

Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse

NCT02123992
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Elevate Apical and Posterior, Native Tissue Repair for pelvic organ prolapse
Device · Procedure
Lead sponsor
ASTORA Women's Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Tucson, Arizona • Newport Beach, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

NCT02601209
View directory record Official record
Conditions
High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Myxofibrosarcoma, Recurrent Leiomyosarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Synovial Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma
Interventions
Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
460
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

NCT00032929
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
16
States / cities
Tucson, Arizona • Berkeley, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 2:24 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

NCT05087056
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 14 Years
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

NCT04740931
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 22, 2026, 2:24 PM EDT
No Longer Available No phase listed Expanded access

Atazanavir for HIV Infected Individuals: An Early Access Program

NCT00046345
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir (BMS-232632)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
163
States / cities
Hobson City, Alabama • Anchorage, Alaska • Phoenix, Arizona + 158 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

NCT04134936
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Tafasitamab plus lenalidomide
Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Anaheim, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

NCT02080364
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
80
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 1 Interventional

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

NCT01677572
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 90 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02785939
View directory record Official record
Conditions
CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, Laboratory Biomarker Analysis, Palbociclib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1065
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 22, 2026, 2:24 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

NCT02045901
View directory record Official record
Conditions
Morning Sickness
Interventions
Diclegis, Placebo (Sugar Pill)
Drug
Lead sponsor
Duchesnay Inc.
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Norwalk, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 22, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

NCT00303563
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
P38 Inhibitor (4), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Anniston, Alabama • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 2:24 PM EDT